Critical Breathes Easier After Finding Promotion Partner For Pending Asthma Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal with Merck KGaA subsidiary DEY for zileuton CR adds more than 200 reps and expertise in detailing to respiratory physicians.
You may also be interested in...
FDA Asks Genentech To Add Boxed Anaphylaxis Warning To Xolair Label
Continued post-marketing reports of anaphylaxis, some well after treatment, led agency to ask for label revision.
Critical Therapeutics Seeks Co-Promotion Partner For Zileuton CR
The company will downsize Zyflo sales force ahead of expected approval of twice-daily zileuton for asthma.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.